Mint Tower Capital Management B.V. Acquires New Position in Penumbra, Inc. $PEN

Posted by George Bondi on Aug 29th, 2026

Mint Tower Capital Management B.V. bought a new position in shares of Penumbra, Inc. (NYSE:PEN – Free Report) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 5,019 shares of the company’s stock, valued at approximately $1,585,000.

A number of other large investors have also recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Penumbra in the 2nd quarter valued at $1,356,953,000. Geode Capital Management LLC lifted its position in shares of Penumbra by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 766,510 shares of the company’s stock worth $238,365,000 after buying an additional 18,738 shares during the last quarter. Invesco Ltd. lifted its position in shares of Penumbra by 1.1% during the 4th quarter. Invesco Ltd. now owns 638,305 shares of the company’s stock worth $198,455,000 after buying an additional 7,211 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in Penumbra by 165.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 594,112 shares of the company’s stock valued at $184,715,000 after buying an additional 370,636 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Penumbra by 1.5% in the fourth quarter. Janus Henderson Group PLC now owns 475,898 shares of the company’s stock valued at $147,962,000 after buying an additional 7,050 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Trading Up 0.2%

Shares of PEN stock opened at $321.58 on Friday. Penumbra, Inc. has a twelve month low of $221.26 and a twelve month high of $362.41. The stock’s fifty day simple moving average is $320.71 and its 200 day simple moving average is $326.86. The company has a quick ratio of 3.86, a current ratio of 5.75 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $12.67 billion, a P/E ratio of 79.01, a P/E/G ratio of 1.99 and a beta of 0.70.

Penumbra (NYSE:PEN – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.88 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.28). Penumbra had a net margin of 10.67% and a return on equity of 10.50%. The firm had revenue of $390.05 million during the quarter, compared to the consensus estimate of $389.64 million. During the same quarter in the prior year, the business posted $0.86 earnings per share. Penumbra’s revenue for the quarter was up 14.9% compared to the same quarter last year. As a group, sell-side analysts predict that Penumbra, Inc. will post 5.02 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PEN has been the subject of several research analyst reports. Zacks Research raised Penumbra from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. Royal Bank Of Canada restated a “sector perform” rating and issued a $374.00 price target on shares of Penumbra in a research note on Thursday, June 11th. Evercore reaffirmed an “outperform” rating and set a $320.00 price target on shares of Penumbra in a report on Monday, July 6th. Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Penumbra in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. According to MarketBeat.com, Penumbra currently has a consensus rating of “Hold” and an average price target of $367.07.

View Our Latest Research Report on Penumbra

Penumbra Profile

(Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

Mint Tower Capital Management B.V. Acquires New Position in Penumbra, Inc. $PEN

Penumbra Trading Up 0.2%

Analyst Upgrades and Downgrades

Penumbra Profile

Further Reading

You might be interested in: